Stocktoria
MANGOCEUTICALS, INC. MGRX
MANGOCEUTICALS, INC. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $456,021 | $615,873 | $731,493 | $8,939 |
| Gross profit | $250,386 | $379,964 | $431,501 | $4,850 |
| Operating income | -$18.0M | -$8.0M | -$9.2M | -$2.0M |
| Interest expense | — | — | -$6,473 | $6,473 |
| Net income | -$20.6M | -$8.7M | -$9.2M | -$2.0M |
| EPS (diluted) | $-2.17 | $-4.80 | $-8.58 | $-0.19 |
| Operating cash flow | -$5.9M | -$4.9M | -$7.0M | -$1.3M |
| Free cash flow | — | — | -$7.0M | -$1.4M |
| Cash & equivalents | $1.5M | $58,653 | $739,006 | $682,860 |
| Inventory | — | — | $18,501 | — |
| Total assets | $16.1M | $15.4M | $1.1M | $1.0M |
| Total liabilities | $890,568 | $1.4M | $276,039 | $389,257 |
| Shareholders' equity | $15.2M | $13.9M | $774,754 | $614,030 |
Growth · year-over-year · Revenue CAGR 270.9%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | -26.0% | -15.8% | +8083.2% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.